Multiple Myeloma Trial of Orally Administered Salmonella Based Survivin Vaccine

PHASE1CompletedINTERVENTIONAL
Enrollment

1

Participants

Timeline

Start Date

August 6, 2021

Primary Completion Date

March 22, 2022

Study Completion Date

August 5, 2024

Conditions
Multiple Myeloma
Interventions
BIOLOGICAL

CVD908ssb-TXSVN

"TXSVN may activate the immune system which is the participants body's ability to fight disease, and help develop a response against cancer cells that express Survivin. Survivin has been safely targeted using immune cells, drugs or direct inhibitors in over 50 patients with cancers in published reports.~Survivin belongs to the group of proteins known as tumor-associated antigens (TAAs). These are cell proteins that are specific to the cancer cell. They either are not found or are found in low levels normal cells in the human body. More than 90% of myeloma cancer cells have been shown to possess large quantities of Survivin."

Trial Locations (1)

77030

Houston Methodist Hospital, Houston

All Listed Sponsors
collaborator

Center for Cell and Gene Therapy, Baylor College of Medicine

OTHER

collaborator

The Methodist Hospital Research Institute

OTHER

lead

Baylor College of Medicine

OTHER

NCT03762291 - Multiple Myeloma Trial of Orally Administered Salmonella Based Survivin Vaccine | Biotech Hunter | Biotech Hunter